Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
Another GLP-1/GIP/glucagon receptor triagonist known as retatrutide (previously LY3437943) was developed by Eli Lilly in 2022 leading to weight loss, reduced fat mass, decreased blood glucose and insulin levels in obese mice, which was attributed to increased energy expenditure and lipid oxidation [62]
Monitor blood sugar closely, especially during dose changes, as the combination of reduced food intake and improved insulin sensitivity can increase hypoglycemia risk
Risk factors include renal impairment, severe hepatic disease, acute heart failure, heavy alcohol use, and conditions causing tissue hypoxia
KLOW is supplied as a lyophilized (freeze-dried) powder in a sterile glass vial sealed with a rubber stopper
